31 January 2023 - 31 January is set to mark the start of a watershed year for the biosimilars industry with the release of Amjevita, the first biosimilar for Humira, the world’s best selling drug. Several more Humira biosimilars will also be released this year.
But without support from regulators and policy makers to make all biosimilars available on formularies, the full promise of these price cutting drugs could be lost, costing the US health care system $133 billion in the next three years.